Adiposity is a key risk factor for a number of common metabolic dis orders, such as type 2 diabetes and cardiovascular disease 1 . Although the recent global increase in adiposity has been driven by lifestyle changes, family and twin studies suggest that there is also a substantial genetic component contributing to interindividual variation in adiposity 2 . The specific loci accounting for this variation are largely unknown.
Stage 2 analyses identify three body fat percentage loci
We examined the associations of the 14 SNPs with body fat per centage in up to 39,576 additional individuals of European descent from 11 studies (stage 2) (Online Methods, Supplementary Table 2 and Supplementary Fig. 1 ). In a joint metaanalysis of stage 1 and stage 2 results, 3 of the 14 SNPs reached genomewide significance (P < 5 × 10 −8 ) for association with body fat percentage ( Table 1 and  Supplementary Table 3) . We confirmed associations for the SNP in FTO (chr16: rs8050136; P all = 3 × 10 −26 ) and for the SNP near IRS1 (chr2: rs2943650; P all = 4 × 10 −11 ), which both reached genomewide significance in stage 1, and identified a third locus near SPRY2, the sprouty homolog 2 gene (chr 13: rs534870; P Europeans = 3 × 10 −8 ). The locus near SPRY2 showed association with body fat percentage only in Europeans and not in Indian Asians, whereas the effect sizes for the loci near IRS1 and in FTO were similar in metaanalyses of Europeans only compared to Europeans and Indian Asians combined ( Table 1 and Supplementary Table 4 ). The association of the SNP near IRS1 with body fat percentage was significantly (P sexdifference = 0.02) more pronounced in men (P = 3 × 10 −11 ) than in women (P = 9 × 10 −3 ) ( Table 1 and Supplementary Table 3) . Whereas FTO is a wellestablished adiposity gene 3, 5 , the loci near IRS1 and SPRY2 have not been previously implicated in adiposity. Therefore, we focused our followup analyses on the loci near IRS1 and SPRY2 to estimate their impact on related metabolic traits and to gain insight into the potential functional roles of these two new adiposity loci.
Follow up of the locus near IRS1
rs2943650 near IRS1 was associated with a 0.16% lower body fat per centage per copy of the major allele. The effect was stronger in men than in women (β = 0.20% and β = 0.06% per allele, respectively). Notably, despite the highly significant associations with body fat per centage, we found no convincing evidence of association between the SNP near IRS1 and BMI (P all = 0.32, P men = 0.16 and P women = 0.79) or other obesityrelated traits (Supplementary Table 5 ). As BMI represents both fat and lean mass, whereas body fat percent age is a measure of the relative proportion of these two tissues, our observation suggests that the locus near IRS1 specifically influences We defined genome-wide significance as P < 5 × 10 −8 . The effect allele for each locus is the body fat percentage decreasing (major) allele. Chromosomal positions are indicated according to build 36 and allele coding based on the positive strand. Chr., chromosome; NA, no individuals available for analysis.
a Effect sizes in percentages obtained from stage 2 studies only, which included only individuals of European descent.
A r t i c l e s adiposity, or alternatively, influences fat mass and lean body mass in opposite directions. rs2943650 is located 500 kb upstream of IRS1, an important medi ator of insulin and insulinlike growth factor1 (IGF1) signaling (Fig. 2) . Previous GWAS have identified SNPs near IRS1, which are in high LD with rs2943650 (r 2 > 0.8 in the HapMap European CEU popu lation), to be associated with various metabolic traits [9] [10] [11] . Notably, although we observed the major allele of rs2943650 to be associated with lower body fat percentage, prior work suggests that the major allele of rs2972146 (r 2 = 0.95 with rs2943650) is associated with higher triglycerides and lower highdensity lipoprotein (HDL) cholesterol 9 , that the major allele of rs2943641 (r 2 = 1.00 with rs2943650) is asso ciated with increased insulin resistance and risk of type 2 diabetes 10 and that the major allele of rs2943634 (r 2 = 0.83 with rs2943650) is associated with increased risk of coronary artery disease 11 .
To better understand how genetic variation in the locus near IRS1 is associated with both lower body fat percentage and a more adverse met abolic profile, we performed a series of focused followup analyses on the association of rs2943650 with lipid profiles, indices of insulin sensi tivity, fat distribution and circulating levels of leptin and adiponectin in the stage 2 studies that had all or some of these traits measured (Online Methods and Supplementary Fig. 1 ). These analyses confirmed that the bodyfatpercentage-decreasing allele of rs2943650 is associated with higher triglycerides and lower HDL cholesterol levels and with increased insulin resistance, as indicated by the increased ratio of insulin area under the curve (AUC) to glucose AUC and decreased Matsuda 12 and Gutt 13 insulin sensitivity indexes ( Fig. 3 and Supplementary Table 6 ). Consistent with the sex difference observed for the association of rs2943650 with body fat percentage, the associations with HDL cho lesterol and triglyceride levels were more pronounced in men (n = 9,937 and n = 10,659, respectively) than in women (n = 10,659 and n = 10,848, respectively) (P sexdifference = 0.027 and P = 0.025, respectively) ( Fig. 3 and Supplementary Table 6 ), whereas associations with indices of insulin resistance were similar in both sexes.
To examine whether the association of the locus near IRS1 with body fat percentage is mediated through association with insulin sensitivity, we performed an analysis for body fat percentage adjusted for insulin sensitivity among 6,489 men of the METSIM (Metabolic Syndrome in Men) study (Supplementary Fig. 3) . Similarly, to examine whether the association of IRS1 with body fat percentage could explain association with insulin sensitivity, we carried out an analysis for insulin sensitiv ity adjusted for body fat percentage. Although the effect size for the association of the rs2943650 (near IRS1) major allele with reduced body fat percentage did not significantly (P difference = 0.38) change after Figure 1 Manhattan plot showing the significance of association with body fat percentage for SNPs in the stage 1 meta-analysis of all individuals (n = 36,626). SNPs are plotted on the x axis according to their position on each chromosome against association with body fat percentage on the y axis (shown as −log 10 P). The loci highlighted in blue are the 11 loci that reached an association P < 10 −6 in the stage 1 meta-analysis of all individuals, Europeans, men or women and were taken forward for followup analyses but did not achieve genome-wide significance (P < 5 × 10 −8 ) in the meta-analyses combining GWAS and follow-up data. The three loci colored in red are those that reached genome-wide significant association (P < 5 × 10 −8 ) in the meta-analyses combining GWAS and follow-up data. Figure 2 Regional plot of the loci near IRS1, near SPRY2 and in FTO that reached genome-wide significant evidence for association with body fat percentage. The plotted data for the locus near SPRY2 are from the meta-analysis of individuals of European descent only, and the data for the loci near IRS1 and in FTO are from the meta-analysis of all individuals. The rs2943650 (near IRS1), rs534870 (near SPRY2) and rs8050136 (FTO) SNPs that showed the strongest association with body fat percentage are indicated. For the locus near IRS1, rs2972146, rs2943641 and rs2943634, which have been associated with blood levels of HDL cholesterol and triglycerides 9 , risk of type 2 diabetes 10 and risk of coronary artery disease 11 , respectively, in GWAS meta-analyses, are also indicated. The plot was generated using LocusZoom 44 (see URLs).
A r t i c l e s adjusting for insulin sensitivity, the association with reduced insulin sensitivity became significantly stronger when we adjusted for body fat percentage (P difference = 0.035). These observations suggest that the locus near IRS1 may have a primary effect on body fat percentage and that the association with decreased insulin sensitivity is partly medi ated by changes in body fat percentage, at least in men.
We next examined whether the concurrent association of the locus near IRS1 with lower body fat percentage and an adverse metabolic profile could be caused by joint associations with body fat distribution. Therefore, we determined associations of rs2943650 with abdominal visceral and subcutaneous fat obtained by computerized tomography in the GWAS metaanalysis data of 10,557 individuals (C.S.F., I.B.B., Y.L. & T.B.H., data not shown). We found that the locus near IRS1 was associated with an adverse distribution of body fat in men, mean ing the bodyfatpercentage-decreasing allele reduced subcutaneous fat in men (P = 1.8 × 10 −3 , n = 4,997) but not in women (P = 0.063, n = 5,560), whereas we observed no association with visceral fat in either men (P = 0.95) or in women (P = 0.63). Most evidently, the bodyfat-decreasing allele of the locus near IRS1 was associated with a higher ratio of visceral adipose tissue to subcutaneous adipose tissue in men (P = 6.1 × 10 −6 ) but not in women (P = 0.31). Our data thus suggest that the locus near IRS1 may associate with a reduced storage of subcutaneous fat in men, which could contribute to the associations of this locus with insulin resistance and dyslipidemia by leading to an ectopic deposition of lipids 13 .
Having shown association of the locus near IRS1 with the quantity and distribution of body fat and with related metabolic traits, we aimed to determine whether this locus is associated with measures of adipocyte function. Leptin and adiponectin are two hormones (adipokines) produced exclusively in adipose tissue that respond in a reciprocal manner to changes in fat mass and insulin resist ance. Higher levels of leptin and lower levels of adiponectin corre late with increased body fat and insulin resistance 14 . Leptin data was available for 4,641 individuals, and adiponectin data was avail able for 9,769 individuals participating in our stage 2 metaanalysis (Online Methods and Supplementary Fig. 1) . Notably, the bodyfat percentage-decreasing allele was associated with lower adiponectin levels in men (P = 6.1 × 10 −6 , n = 8,681), which is in contrast to what we expected given the inverse correlation between body fat percent age and adiponectin levels. We observed no association with lower adiponectin levels in women (n = 1,088), which was significantly different from the association in men (P sexdifference = 0.040) ( Fig. 3 and Supplementary Table 6 ). The association between the locus near IRS1 and leptin levels was not significant, which could be because of low statistical power, as the size of the sample available was small ( Fig. 3 and Supplementary Table 6) . Notably, recent studies in leptin deficient (ob/ob) mice have shown that transgenic overexpression of adiponectin permits metabolically healthy expansion of subcutaneous adipose tissue, preventing accumulation of lipids in liver and retaining insulin sensitivity 15 . Vice versa, we speculate that the lower adiponec tin levels, seen in men with the fatpercentage-decreasing allele of the locus near IRS1, might be associated with the lack of ability to expand subcutaneous adipose tissue, leading to a flux of lipids into liver and increased insulin resistance through a lipotoxic mechanism 16 .
To examine whether rs2943650 modifies the function of IRS1, we studied gene expression profiles within subcutaneous adipose tissue and blood from 604 Icelandic individuals (the deCODE cohort) 6, 17 , within liver (n = 567), subcutaneous (n = 610) and omental (n = 742) adipose tissue from individuals who underwent bariatric surgery 18 , and within normal cortical brain samples of 193 indivi duals of European descent 19 (Online Methods). We found that the bodyfatpercentage-decreasing allele is associated with lower IRS1 expression in subcutaneous and omental adipose tissue but not in liver, brain or blood (Supplementary Table 7 and Supplementary  Fig. 4 ). The association with reduced expression in subcutaneous and omental adipose tissues seemed more pronounced in men than in women. Previous studies have shown that the bodyfatpercent age-decreasing allele of rs2943641 in the same locus (r 2 = 1.0 with rs2943650) is associated with reduced expression of IRS1 protein and reduced insulininduced phosphatidylinositol 3OH kinase activity in skeletal muscle 10 .
Finally, to determine if there is a sex difference in the adipose tissue expression of IRS1, we analyzed gene expression in isolated adipocytes from male and female mice. The data showed that adipocytes from females express higher levels of Irs1 than adipocytes from males in both visceral and subcutaneous fat depots (Supplementary Fig. 5 ). We followed up this finding in human adipose tissue and found that the expression of IRS1 was significantly greater in visceral adipose tissue from women (n = 75) than in visceral fat from men (n = 26), whereas we saw no sex difference in IRS1 expression in subcutane ous adipose tissue (Supplementary Fig. 6 ). The higher basal levels of IRS1 in female adipose tissue could, at least in theory, buffer women against the modest impairment of IRS1 expression associated with genetic variation near IRS1.
Follow up of the locus near SPRY2 rs534870, which reached P = 3 × 10 −8 in our metaanalysis of European individuals only, is located 54 kb downstream of SPRY2 with no other genes nearby (Fig. 2) . The bodyfat-decreasing (major) allele of rs534870 was associated with a 0.14% decrease in body fat Figure 3 Association of the body-fatpercentage-decreasing (T) allele of rs2943650 near IRS1 with blood lipids, insulin sensitivity traits, leptin and adiponectin. The error bars indicate 95% confidence intervals. All traits were inverse normally transformed to approximate normality (mean = 0, s.d. = 1) in men and women separately. All models were adjusted for age and age squared. The numeric values for the associations are presented in supplementary table 6 . We found a significant difference between men and women for the levels of HDL cholesterol (P = 0.027), triglycerides (P = 0.025) and adiponectin (P = 0.040). InsAUC/GluAUC, insulin area under the curve (AUC) to glucose AUC ratio.
percentage. Unlike for the locus near IRS1, the association was similar in men and women (P sexdifference = 0.62), and we observed no associa tion in Indian Asians ( Table 1) . We found a modest association for rs534870 with BMI, body weight and risk of obesity in a metaanalysis of all stage 2 studies (Supplementary Table 8 ). There was no associa tion between the locus near SPRY2 and blood lipids, but we found a nominally significant association between the bodyfatpercentagedecreasing allele and increased insulin sensitivity measured with the Gutt insulin sensitivity index 13 (Supplementary Table 8 ). The asso ciation with Gutt index was not significant after adjustment for body fat percentage (P = 0.2). The bodyfatpercentage-decreasing allele of rs534870 was modestly associated with decreased SPRY2 expression in whole blood. In contrast with the locus near IRS1, there was no association between rs534870 and SPRY2 expression in adipose tissue, brain or liver (Supplementary Table 7 and Supplementary Fig. 4) .
SPRY2 encodes a negative feedback regulator of the Ras/mitogen activated protein kinase pathway 20 . At the cellular level, overexpres sion of SPRY2 inhibits migration and proliferation of a variety of cell types in response to serum and growth factors [21] [22] [23] . Recent studies have identified Spry1, a homolog of Spry2, as a critical regulator of adipose tissue differentiation in mice 24 . The loss of Spry1 function resulted in a low bone mass and high body fat phenotype.
Established obesity loci and body fat percentage
Previous GWAS have examined BMI as an index of adiposity [3] [4] [5] [6] [7] [8] , and the recent metaanalysis by the GIANT (Genetic Investigation of Anthropometric Traits) Consortium increased the total number of established BMI susceptibility loci to 32 (ref. 8) . The associations of the 32 confirmed BMI loci with body fat percentage were all direc tionally consistent with the previously established BMI associations (binomial sign test P < 0.0001), and associations for 17 of these loci reached nominal statistical significance (Supplementary Table 9 ). Our stage 1 sample size of 36,626 individuals was small compared to the GIANT stage 1 metaanalysis of BMI, which included 123,865 individuals, and we thus had insufficient power to confirm all 32 loci as bodyfat-percentage loci. Furthermore, as BMI is a composite trait of fat and lean mass, BMI loci may associate with BMI by increasing fat mass, lean mass or both. Disentangling whether the established BMI loci associate with body fat percentage per se or with body mass overall will require larger sample sizes.
Other GWAS have identified three loci associated with waist cir cumference 25, 26 and five loci associated with extreme obesity 27, 28 . Similar to BMI loci, the associations of these eight loci with body fat percentage were directionally consistent with the previously estab lished associations (binomial sign test P = 0.008), and associations for one waist circumference locus and two extreme obesity loci reached nominal significance (Supplementary Table 9) .
Apart from GWAS that examined traits related to overall adiposity, recent GWAS studies have identified 14 loci associated with waistto hip ratio adjusted for BMI 26, 29 , a measure of body fat distribution. We found no association between these waisttohip loci and increased body fat percentage (Supplementary Table 9) , which is consistent with the observation that these 14 loci are not or only very weakly associated with BMI and likely due to the fact that these loci were identified after accounting for BMI in the analyses.
DISCUSSION
Using a twostage genomewide association metaanalysis including up to 76,150 individuals, we identified three loci convincingly associ ated with body fat percentage. Although FTO was previously estab lished as an obesity susceptibility locus 3,5 , the loci near IRS1 and near SPRY2 have not previously been identified in the largescale GWAS for BMI 8 , waist circumference 25, 26 , waisttohip ratio 26, 29 or extreme obesity 27, 28 , suggesting that these loci have a specific association with body fat percentage.
The locus near IRS1 is associated with lower body fat percentage in men, and more specifically with proportionally less subcutaneous compared to visceral fat. Of particular interest is the pattern of asso ciation with other metabolic traits, which was opposite to what would be expected based on the known association between lower body fat percentage and improved metabolic profile. In effect, the fat percentage-decreasing allele of the locus near IRS1 was associated with higher levels of insulin resistance, an adverse lipid profile and lower levels of adiponectin in men. Furthermore, the fatpercentagedecreasing alleles of SNPs in the locus near IRS1 have previously been associated with increased risk of type 2 diabetes 10 and coronary artery disease 11 .
We, and others 10 , showed that genetic variation near IRS1 is asso ciated with reduced IRS1 expression in major insulin target tissues, including adipose tissue and muscle, which may explain the asso ciation of this locus with increased wholebody insulin resistance and risk of type 2 diabetes. The locus near IRS1 is one of the few loci thought to increase risk of type 2 diabetes through an effect on insulin resistance, whereas other diabetes loci predominantly asso ciate with measures of impaired betacell function 10, 30 . However, the mechanisms linking the locus near IRS1 with type 2 diabetes may be more complex than previously thought. Our data suggest that genetic variation near IRS1 may be associated with a reduced ability to store subcutaneous fat, at least in men, which may partly explain the association with wholebody insulin resistance and dys lipidemia. Adiposetissue insulin sensitivity itself has little impact on wholebody insulin sensitivity, which is largely determined by the liver and muscle 31 . However, impaired ability of subcutaneous adipose tissue to expand may disrupt insulin signaling in liver and muscle by leading to ectopic deposition of lipids 32 . Such an indirect mechanism could exacerbate the intrinsic impairment of IRS1 sig naling in muscle.
The association of the locus near IRS1 with body fat percentage and with many of the metabolic traits was more pronounced in men than in women. The mechanistic basis for this sexual dimorphism is yet unclear but may be related to the powerful drive to subcutaneous adipogenesis in women compared to men, which may overcome a defect in IRS1 function. Men tend to deposit less subcutaneous and more visceral fat than women 33 , and IRS1 may thus have a stronger role in the regulation of subcutaneous fat in men. The association of the locus near IRS1 with the expression of IRS1 in subcutaneous adipose tissue was more pronounced in men, indicating that there may be sex differences in the effects of the locus near IRS1 on gene function itself. We also showed a sex difference in both mouse and human adipose tissue expression of IRS1, with adipose tissue from females showing greater IRS1 expression. IRS1 function has been described in animal models. Knockout of Irs1 in mice leads to hyperinsulinemia and mildtomoderate insulin resistance despite a lean phenotype 34, 35 . IRS2 (ref. 36 ) and IRS3 (refs. 37,38) partly compensate for the lack of IRS1. Knockout of Irs1 and Irs3 together leads to severe early onset lipoatrophy with marked hyperglycemia, hyperinsulinemia and insulin resistance 39 . The gene encoding IRS3 is lacking in humans, which may make humans more dependent on IRS1. Data from cell lines of Irs1 knockout animals suggest that Irs1 is involved in adipocyte differentiation 40, 41 . In Irs1 knockout mice, the ability of embryonic fibroblast cells to differentiate into adipocytes is reduced by 60% 40 . Cells of knockout mice for both
A r t i c l e s
Irs1 and Irs2 are completely unable to differentiate into adipocytes and show a severe reduction in white adipose tissue soon after birth 40 .
Our second new locus for body fat percentage, near SPRY2, showed association only in Europeans and not in Indian Asians. Different from the locus near IRS1, the association between the bodyfat percentage-decreasing allele of the locus near SPRY2 and insulin resistance was in the expected direction, meaning this allele associated with higher insulin sensitivity, and adjustment for body fat percentage attenuated the association. Similar to the locus near IRS1 (refs. 40,41) , the locus near SPRY2 may play a role in regulating adipose tissue dif ferentiation 24 . Different from the GWAS of BMI, which have mainly established loci mechanistically linked with central nervous system control of appetite and energy expenditure 8 , our metaanalysis of body fat percentage indicates that loci harboring genes with potential links with adipocyte physiology may also play important roles in the regulation of body adiposity.
Our stage 1 metaanalyses included individuals of European and of Indian Asian descent. The Indian Asian individuals were mainly of north Indian descent ('ancestral north Indians' , a western Eurasian population) and thus more closely related to Europeans, and, to a lesser extent, to Asians ('ancestral south Indians') 42 . Furthermore, the overall body fat percentage of the Indian Asian sample did not differ from that of individuals of European descent in our study. However, despite some similarities, genetic differences between European and IndianAsian populations remain, and as differences in body com position between both ethnicities have been documented 43 , we also performed a stage 1 GWAS in Europeans only. Exclusion of the Indian Asians did not affect the associations observed for the locus near IRS1, but it did for the locus near SPRY2. More specifically, the locus near IRS1 was associated with body fat percentage in individuals of European and of IndianAsian descent at stage 1. The association for the locus near SPRY2, however, was only seen in Europeans, whereas we saw no association in Indian Asians. These observations illustrate the value of including the IndianAsian sample, as stratified analyses allowed us to infer the ethnic specificity of the identified loci.
In summary, we identified a locus near IRS1 that is associated with reduced body fat percentage and adipose tissue IRS1 expression in men but also with a combination of adverse metabolic and disease risk traits, including lower levels of subcutaneous fat, increased insulin resistance, dyslipidemia, decreased circulating levels of adi ponectin and increased risk of diabetes and coronary artery disease. Furthermore, genetic variation in a locus near SPRY2 associates with body fat percentage in individuals of European descent. Our findings provide new insights into adiposity and insulin resistance. 
ONLINE METhODS
Study design. We designed a multistage study (Supplementary Fig. 1 ) com prising a GWAS metaanalysis for body fat percentage (stage 1) of data of up to 36,626 individuals of European (n = 29,069) or IndianAsian (n = 7,557) descent from 15 studies and selected 14 SNPs with P < 1 × 10 −6 for follow up in stage 2. Stage 2 comprised up to 34,556 additional European individuals from 11 studies. Body fat percentage in stage 1 and stage 2 cohorts was measured either with bioimpedance analysis (BIA) or dual energy Xray absorptiometry (DEXA), as described in the Supplementary Note. To explore the comparabil ity of the methods, we studied the correlation between body fat percentage obtained by DEXA and BIA in the Fenland study (n = 2,535), in which both measurements were taken at the same time point. The Fenland study is a populationbased cohort of European men and women between the ages of 30 and 60 years (Supplementary Note). The Pearson correlation coefficient showed that the DEXA and BIA measurements of body fat percentage are highly correlated (r = 0.92). The correlation between body fat percentage with BMI was moderate (r = 0.62 measured by DEXA and r = 0.58 measured by BIA, respectively).
Metaanalysis of stage 1 and 2 summary statistics identified three loci that reached genomewide significance (P < 5 × 10 −8 ) for association with body fat percentage. Two of these loci (near IRS1 and near SPRY2) had not been previously identified in genomewide association studies for BMI 8 , waist cir cumference 25, 26 , waisttohip ratio 26, 29 or extreme obesity 27, 28 . Subsequently, we performed a series of focused followup analyses (stage 3) to estimate the impact of these two new established body fat percentage loci and to explore their potential functional roles.
Stage 1 genome-wide association meta-analysis of body fat percentage.
Genotyping. The 15 studies included in the stage 1 metaanalysis were geno typed using Affymetrix, Illumina and Perlegen wholegenome genotyping arrays (Supplementary Note). To allow for metaanalysis across different marker sets, imputation of polymorphic HapMap European CEU SNPs was performed using MACH 45 , IMPUTE 46 or BIMBAM 47 (Supplementary Note). IndianAsian genotype data in the LOLIPOP study was imputed using pooled haplotypes from all three HapMap populations (CEU, YRI and JPT+CHB). Imputation scores for the successful SNPs were slightly lower for Indian Asians than for Europeans. The IndianAsian GWAS of men genotyped with the Illumina 610K array had an average r 2 hat of 0.942, whereas the GWAS from the GOOD study, genotyped with the same chip, had an average r 2 hat of 0.956. In the IndianAsian GWAS genotyped with the Perlegen array, the average r 2 hat was 0.751, whereas it was 0.851 in the European GWAS sample from the same study, genotyped with the same chip. In previously published data 48 , comparisons of imputed and experimentally derived genotypes in Indian Asians yielded an estimated imputation error rate of 2.86% per allele and an estimated average r 2 hat of 89.8%
Association analysis with body fat percentage. Each study performed single marker association analyses with body fat percentage using an additive genetic model implemented in MACH 45 , Merlin 49 , SNPTEST 46 or PLINK 50 . Body fat percentage was adjusted for age and age squared and inverse normally trans formed to a mean of 0 and an s.d. of 1. Analyses were stratified by sex. To allow for relatedness in the Framingham Heart, Amish HAPI Heart, Family Heart and Erasmus Rucphen studies, regression coefficients were estimated in the context of a variance component model that modeled relatedness in men and women combined with sex as a covariate. In the Twins UK study, only one twin was randomly selected for the analyses from monozygotic twin pairs, whereas from dizygotic twin pairs, both twins were used for the analyses. Association analyses accounted for the relatedness between dizygotic twin pairs.
Before performing metaanalyses on the genomewide association data for the 15 studies, SNPs with poor imputation quality scores (r 2 hat < 0.3 in MACH, proper_info < 0.4 in IMPUTE or the ratio of observed to expected dosage variance < 0.3 in BIMBAM) were excluded for each study. All individual GWAS were genomic control corrected before metaanalysis. Individual studyspecific genomic control values ranged from 0.979 to 1.052 (Supplementary Note).
Meta-analysis of stage 1 association results. Next, we performed the stage 1 metaanalyses using the inverse variance method, which is based on β coeffi cients and standard errors from each individual GWAS. The metaanalyses were performed for all individuals combined, for European individuals, for men and for women using METAL (see URLs). The genomic control values for the meta analyzed results were 1.074, 1.065, 1.052 and 1.040 in all individuals, European individuals, men and women, respectively (Supplementary Fig. 7) .
Selection of SNPs for follow up. Fourteen SNPs, representing the 14 most significant (P < 1 × 10 −6 ) independent loci in all individuals, Europeans, men or women ( Table 1 and Supplementary Fig. 2 ) were selected for replication analyses (stage 2). Loci were considered independent when they were in low LD (r 2 < 0.3) or were >1 Mb apart. SNPs which had been genotyped in less than 50% of the samples and/or that had a minor allele frequency <0.5% were excluded. For some loci, the SNP with the strongest association could not be genotyped for technical reasons and was substituted by a proxy SNP that was in high LD with it (r 2 > 0.8) according to the HapMap CEU data. We tested the association of these 14 SNPs in four de novo and seven in silico replication studies in stage 2.
Test for sex difference. The differences between the effect sizes in men and women for the strongest signals were assessed with a t test with additional correction for the correlation between β coefficients in men and women in the GWAS data as follows: 46 . SNPs with poor imputation quality scores from the in silico studies (r 2 hat < 0.3 in MACH or proper_info < 0.4 in IMPUTE) were excluded. Association analyses and meta-analysis. We tested the association between the 14 SNPs and body fat percentage in each in silico and de novo stage 2 study separately as described for the stage 1 studies. We subsequently performed a metaanalysis of β coefficients and standard errors from the stage 2 studies using the inverse variance method. Data was available for at least 31,705 indi viduals for 11 SNPs, except for three SNPs (rs17149412 in FDFT1, rs7736910 near HTR1A and rs7738021 near MARCH3), for which data was only avail able for ~24,400 individuals because of technical challenges relating to the genotyping and imputation of these SNPs. Next, we performed a metaanalysis of the summary statistics of the stage 1 and stage 2 metaanalyses using the inverse variance method in METAL. Differences in effect sizes between men and women were assessed as in stage 1. Fig. 1 and Supplementary Note). Additional analyses for waist circumference, hip circumference and waisttohip ratio were performed in three of the stage 2 studies (EPICNorfolk, Fenland and MRC Ely) (Supplementary Fig. 1 ). The associations of the SNPs with quan titative secondary traits (BMI, body weight, height, waist circumference, hip circumference and waisttohip ratio) were tested with linear regression. The associations with overweight or obese status were assessed using logistic regres sion. All quantitative traits were analyzed as nontransformed data. All tests assumed an additive genetic model and were stratified by sex, adjusting for age and age squared. Summary statistics (β coefficients and standard errors) were metaanalyzed using the inverse variance method of METAL (see URLs).
Evidence for association of the locus near IRS1 with subcutaneous and visceral fat, obtained by computerized tomography from 10,557 individuals, was extracted from another GWAS metaanalysis (C.S.F., I.B.B., Y.L. & T. B.H., data not shown).
Associations with blood lipids. Associations of the loci near IRS1 and SPRY2 with blood levels of HDL cholesterol, triglycerides and lowdensity lipoprotein (LDL) cholesterol were examined in three of the stage 2 studies, including EPICNorfolk, Fenland and MRC Ely (Supplementary Fig. 1 ). In the EPIC Norfolk Study, HDL cholesterol and triglycerides were measured from non fasting blood, whereas fasting blood samples were available in the MRC Ely and Fenland studies. The concentration of LDL cholesterol was calculated using the Friedewald formula in all three studies. The associations of the SNPs with lipid levels were tested with linear regression in men and women sepa rately, assuming an additive genetic model and adjusting for age, age squared and the use of lipid lowering medication. An inverse normal transformation for lipid levels was performed in men and women separately before the analy ses. Summary statistics (β coefficients and standard errors) were pooled using the inverse variance metaanalysis method of METAL (see URLs).
Associations with insulin sensitivity traits. The associations of the locus near IRS1 with insulin sensitivity traits (M/I ratio, with glucose infused (M) derived by the circulating insulin concentration (I); insulin area under the curve (AUC) to glucose AUC ratio; Matsuda insulin sensitivity index 12 ; and Gutt insulin sensitivity index 13 ) were examined in five studies (Metabolic Syndrome in Men (METSIM), MRC Ely, Relationship between insulin sensitivity and cardiovas cular disease risk (RISC), Uppsala Longitudinal Study of Men (ULSAM) and Whitehall II), of which three (RISC, ULSAM and Whitehall II) were not part of our stage 2 metaanalysis of body fat percentage (Supplementary Fig. 1 ). The RISC and ULSAM studies had data from both euglycemichyperinsulinemic clamps and oral glucose tolerance tests (OGTT), whereas the METSIM, MRC Ely and Whitehall II studies had OGTT data only. The M/I ratios were thus only available from the RISC and ULSAM studies, whereas the three other insulin sensitivity traits were available from all five cohorts. The samples and assays used for the measurement of circulating levels of glucose and insulin are shown in the Supplementary Note. The insulin AUC to glucose AUC ratio and Matsuda and Gutt insulin sensitivity indexes were calculated using data from all available measurement time points. As the Whitehall II cohort had only two measurement time points available, the results from Whitehall II were not included in our metaanalysis of the association between the locus near IRS1 and the insulin AUC to glucose AUC ratio.
Individuals were excluded from the analyses on insulin sensitivity traits if they had selfreported or physiciandiagnosed diabetes or were using oral antidiabetic drugs or insulin. The associations of the SNPs near IRS1 with insulin sensitivity traits were tested with linear regression in men and women separately, assuming an additive genetic model and adjusting for age and age squared. All insulin sensitivity traits were inverse normally transformed in men and women separately before the analyses. Summary statistics (β coef ficients and standard errors) were pooled using the inverse variance meta analysis method of METAL (see URLs).
Associations with leptin and adiponectin levels. The associations of the locus near IRS1 with circulating levels of adiponectin were examined in three studies participating in our stage 2 metaanalysis (METSIM, MRC Ely and Osteoporotic Fractures in Men (MrOS) Sweden) and in the RISC study (Supplementary Note). The samples and assays used for the measurement of leptin and adiponec tin are listed in the Supplementary Note. The associations were tested using linear regression in men and women separately, assuming an additive genetic model and adjusting for age and age squared. Analyses of leptin levels in the MrOS Study were additionally adjusted for study center. Leptin and adiponectin levels were inverse normal transformed in men and women separately before the analyses. Summary statistics (β coefficients and standard errors) were pooled with the inverse variance metaanalysis method of METAL (see URLs).
Expression quantitative trait loci analyses. The gene expression analyses for the loci near IRS1 and SPRY2 in subcutaneous adipose tissue and in whole blood from Icelandic individuals were carried out as described in detail pre viously (GEO database: GSE7965 and GPL3991) 6, 17 . In brief, 603 individuals with adipose tissue samples and 745 blood samples were genotyped with the Illumina 317K or 370K chip. The RNA samples were hybridized to a single custom made human array containing 23,720 unique oligonucleotide probes. Association was tested between the SNPs and the mean logarithm (log 10 ) expression ratio (MLR) adjusting for age, sex and age × sex, as well as for differential cell count in the blood analyses, assuming an additive genetic model and accounting for familial relatedness.
performed in a final volume of 25 µl. The cycle program consisted of an initial denaturing of 10 min at 95 °C, 40 cycles of 15 s denaturizing phase at 95 °C, and 1 min annealing and extension phase at 60 °C. A threshold cycle (Ct value) was obtained for each amplification curve, and a ∆Ct value was first calculated by subtracting the Ct value for human cyclophilin A (PPIA) RNA from the Ct value for each sample. Fold changes relative to the endogenous control were then determined by calculating 2 − ∆ Ct . The gene expression results are thus expressed as an expression ratio relative to PPIA gene expression according to the manufacturers' guidelines.
